PBA
ZLAB icon

Paradigm Biocapital Advisors’s Zai Lab ZLAB Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ZLAB Stock Details ZLAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,091,779
Closed -$29.8M – 37
2023
Q4 		$29.8M Sell
1,091,779
-50,604
-4% -$1.34M 1.4% 20
2023
Q3 		$27.8M Buy
1,142,383
+277,086
+32% +$7.38M 1.88% 20
2023
Q2 		$24M Buy
865,297
+84,739
+11% +$2.77M 1.85% 22
2023
Q1 		$26M Buy
780,558
+265,284
+51% +$10.2M 2.46% 18
2022
Q4 		$15.8M Buy
+515,274
New +$16.3M 1.86% 21

Other funds holding ZLAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Paradigm Biocapital Advisors's ZLAB Position: Q1 2024 in Review

Paradigm Biocapital Advisors sold out of Zai Lab (ZLAB) in Q1 2024, closing a stake of 1,091,779 shares — an estimated $29.8M sold.

Paradigm Biocapital Advisors first reported a position in ZLAB in Q4 2022 and held it in 5 quarters. The position peaked at $29.8M in Q4 2023. 116 funds tracked by Wall St. Rank hold ZLAB as of Q1 2024.

  • Paradigm Biocapital Advisors reported no remaining Zai Lab position as of Q1 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,091,779 Zai Lab shares in Q1 2024, an estimated $29.8M.
  • Paradigm Biocapital Advisors first reported a position in Zai Lab in Q4 2022 and held it in 5 quarters.
  • Paradigm Biocapital Advisors's Zai Lab position peaked at $29.8M in Q4 2023.
  • 116 funds tracked by Wall St. Rank held Zai Lab as of Q1 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2024, filed 15 May 2024.